The aim of this study is to present the proportion of patients with EBC qualifying for adjuvant CDK4/6 inhibitors and their outcomes in terms of OS, iDFS, cumulative incidence of distant recurrence-free survival (DRFS) events, and adherence to ET based on data from the Danish Breast Cancer Group (DBCG) to discuss the potential benefit of adding CDK4/6 inhibitors in the treatment of patients with intermediate- and high-risk disease. The gene discussed is CDK4; the disease is breast cancer.